Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPIV100 and Sargramostim in HER2+ Breast Cancer
NCT04197687Phase 2Unknown
- Sponsor
- Academic and Community Cancer Research United
- Start
- Feb 2020
- Primary completion
- Jan 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in HER2-positive breast cancer comparing TPIV100 + Sargramostim + T-DM1, Placebo + Sargramostim + T-DM1 and Standard of Care (pCR) (3 arms). Primary endpoint: Invasive Disease-Free Survival up to 5 years. Status: unknown.
02
Drugs
TPIV100
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04197687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04197687.